New treatment approved for rare form of hemophilia

(HealthDay)—Obizur (antihemophilic factor recombinant) has been approved to treat a rare, non-inherited form of hemophilia in adults.

Unlike the more common form of that's inherited and affects males, acquired hemophilia affects both males and females. The rarer form of the occurs when the body's immune system attacks a protein that's necessary for normal blood clotting.

About half the cases of acquired hemophilia are related to other , such as pregnancy, cancer or use of certain medications. But about half of cases have no known cause, the FDA said Friday in a news release.

Obizur was evaluated in clinical studies involving 29 adults with acquired hemophilia, who were given Obizur to treat a serious bleeding episode. The trial didn't identify any safety concerns, the FDA said.

Obizur is manufactured by Baxter Healthcare, based in Westlake Village, Calif.

Explore further

New hemophilia remedy offers potential for fewer injections

More information: Visit the FDA to learn more.

Copyright © 2014 HealthDay. All rights reserved.

Citation: New treatment approved for rare form of hemophilia (2014, October 24) retrieved 26 January 2021 from
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Feedback to editors

User comments